OrthoPediatrics (NASDAQ:KIDS) CEO Sells $336,978.75 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David Bailey sold 19,535 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $336,978.75. Following the completion of the sale, the chief executive officer owned 298,020 shares of the company’s stock, valued at approximately $5,140,845. This trade represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OrthoPediatrics Stock Up 0.6%

Shares of KIDS stock traded up $0.10 during trading hours on Tuesday, reaching $17.21. 197,133 shares of the company’s stock were exchanged, compared to its average volume of 152,452. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. The company has a market cap of $435.07 million, a price-to-earnings ratio of -10.18 and a beta of 1.07. OrthoPediatrics Corp. has a fifty-two week low of $15.28 and a fifty-two week high of $26.40. The stock’s 50 day moving average is $17.74 and its 200-day moving average is $17.97.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The firm had revenue of $61.61 million for the quarter, compared to the consensus estimate of $61.27 million. Analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of OrthoPediatrics

Institutional investors have recently made changes to their positions in the company. Millennium Management LLC boosted its stake in OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after purchasing an additional 452,840 shares during the last quarter. Prosight Management LP lifted its stake in shares of OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after buying an additional 235,060 shares in the last quarter. Deerfield Management Company L.P. lifted its stake in shares of OrthoPediatrics by 1,153.4% in the third quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock worth $3,597,000 after buying an additional 178,623 shares in the last quarter. Nantahala Capital Management LLC boosted its position in OrthoPediatrics by 303.3% during the fourth quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock worth $3,542,000 after acquiring an additional 150,000 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in OrthoPediatrics during the 4th quarter valued at about $1,953,000. 69.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KIDS has been the subject of several research reports. TD Cowen upgraded shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price target on OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Canaccord Genuity Group started coverage on OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, Truist Financial raised their price objective on OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OrthoPediatrics has a consensus rating of “Moderate Buy” and an average target price of $24.67.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.